Madrigal Pharmaceuticals (MDGL) Revenue Growth (1y) (2011 - 2026)
Madrigal Pharmaceuticals (MDGL) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 96.43% |
| 10 | Madrigal Pharmaceuticals | 16.14 Bn | 15.91 Bn | - | 126.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.84% |
| Dec 31, 2025 | 210.77% |
| Sep 30, 2025 | 362.03% |
| Jun 30, 2025 | 1,353.76% |
| Sep 30, 2012 | -91.17% |
| Jun 30, 2012 | -30.33% |
| Mar 31, 2012 | -87.14% |
| Dec 31, 2011 | -97.00% |
| Sep 30, 2011 | -50.81% |
| Jun 30, 2011 | -93.72% |